Health Care Sector Update for 12/21/2015: AEGR, RXII
Top Health-care stocks:
Health-care shares were mainly unchanged in pre-market trade on Monday.
In health-care stocks news, biopharmaceutical company Aegerion Pharmaceuticals ( AEGR ) has been upgraded by Guggenheim Securities to a buy rating from a sell. The firm also raised its price target on the stock to $13 from $7 a share.
Shares in the company were 3.2% higher at $9.30 pre-bell. This is within the lower band of the stock's 52 week trading range between $8.68 and $28.97.
And RXI Pharmaceuticals ( RXII ) said it has begun a Phase 2 clinical trial to evaluate the safety and clinical activity of Samcyprone on the clearance of cutaneous warts.
Shares in the company were unchanged at $0.40 pre-bell. This is within the lower band of the stock's 52 week trading range between $0.34 and $1.74.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.